1118 Sublingual Immunotherapy Efficacy in Patients with Atopic Dermatitis in Korea

Wednesday, 14 October 2015
Hall D1 Foyer (Floor 3) (Coex Convention Center)

Jongrok Lee, MD , Gilhospital, Incheon city, South Korea

Jooyoung Roh, MD , Gilhospital, Incheon city, South Korea

Haryeong Ryu , Gilhospital, Incheon city, South Korea

Background: Atopic dermatitis (AD) is currently regarded as an allergic inflammatory disease. Many studies have shown AD to have multiple causes that activate complex immunological and inflammatory pathways. However, aeroallergens, and especially the house dust mite (HDM), play a relevant role in the elicitation or exacerbation of eczematous lesions in many AD patients. Accordingly, allergen-specific immunotherapy has been used in AD patients with the aim of redirecting inappropriate immune responses. Sublingual immunotherapy (SLIT) is especially preferred because of its easy application and safety. The aim of this study was to describe the effect of SLIT in patient with AD.

Methods: Patients with AD who allergic to HDM were evaluated. Patients who allergic to HDM have been treated with SLIT for over 1yr. The effect of patients on clinical course of SLIT with Dermatophagoides pteronyssinus and Dermatophagoides farinae in a standardized extract was assessed and the side effect of SLIT were recorded.

Results: The records of 20 patients (13 males and 7 females) were studied. The mean age for starting SLIT was 16.3 years (aged 6-36 years, median age 13years). Treatment was deemed effective or very effective in 70% of the patients. The majority of the patients were satisfied with their treatment, which was well tolerated. There were no serious side effects except transient nausea, abdominal pain and oral itching sensation in the first few days. SLIT had to be discontinued in 2 patients (10%) because of exacerbation of asthma and dermatitis. Especially, the compliance of patients with AD and allergic rhinitis were better than patients with AD only.

Conclusions: SLIT reduces symptoms of AD, the amount of drug consumption and the progression of the disease. Especially, SLIT is recommendable to patients with AD and allergic rhinitis. We believe SLIT can be an alternative, safe treatment option for allergic AD refractory to long-term conventional treatment